MedPath

Impact of Pre-procedure Cognitive Status on Outcome at 3 Months After Transcatheter Aortic Valve Implantation

Completed
Conditions
Aortic Stenosis
Interventions
Other: MoCA cognitive assessment
Registration Number
NCT04564534
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Brief Summary

This study plans to investigate the relationship between cognitive status pre-procedure, and clinical outcomes at 3 months in patients undergoing transcatheter aortic valve implantation (TAVI).

Detailed Description

This study plans to investigate the relationship between cognitive status pre-procedure, as assessed using the Montreal Cognitive Assessment (MoCA) administered on a tablet, and clinical outcomes at 3 months as assessed by the VARC2 criteria, in patients undergoing transcatheter aortic valve implantation (TAVI)

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
109
Inclusion Criteria
  • Aged 18 years or over
  • Scheduled to undergo TAVI
  • Provide informed consent
  • Able to understand French
Exclusion Criteria
  • subjects under legal guardianship or other legal protection
  • subjects with documented severe dementia
  • subjects with anticipated poor compliance
  • subjects unable to understand French sufficiently well to perform the MoCA test
  • pregnant women
  • subjects within the exclusion period of another study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Study cohortMoCA cognitive assessmentAdult (\>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up. The MoCA will be administered by trained professionals with MoCA certification. Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure.
Primary Outcome Measures
NameTimeMethod
Strokethrough 30 days after the TAVI procedure

Safety outcome at 30 days as assessed by the VARC2 criteria: stroke

All-cause deaththrough 30 days after the TAVI procedure

Safety outcome at 3 months as assessed by the VARC2 criteria: all-cause death

life-threatening bleedthrough 30 days after the TAVI procedure

Safety outcome at 30 days as assessed by the VARC2 criteria: life-threatening bleed

Combined VARC2 safety outcomethrough 30 days after the TAVI procedure

Safety criteria (within 30 days of the procedure) include all-cause death; stroke; life-threatening bleed; renal insufficiency; coronary artery obstruction requiring intervention; major vascular complication; valve dysfunction.

Clinical Efficacy criteria (30 days to 3 months after the procedure) include: all-cause death; stroke; re-admission for valve-rela

Combined VARC2 efficacy outcomethrough 30 days after the TAVI procedure

Clinical Efficacy criteria (30 days to 3 months after the procedure) include: all-cause death; stroke; re-admission for valve-related symptoms or worsening heart failure; NYHA Class III or IV; valve-related dysfunction.

Secondary Outcome Measures
NameTimeMethod
Time required for MoCAAt the time of MoCA completion

Length of time required to administer the MoCA test using a tablet

Relationship between MoCA score and each component of the VARC2At 3 months after TAVI procedure

The relationship between the MoCA and each individual component of the VARC2 will be investigated in bivariable analysis.

Biological parameters pre-procedurepre-procedure

Blood count; prothrombin; TCA; fibrinogen; INR; creatinine; CRP; BNP; TSH; HbA1c; troponin; albumin; GDF15.

Trial Locations

Locations (1)

University Hospital Jean Minjoz

🇫🇷

Besancon, France

© Copyright 2025. All Rights Reserved by MedPath